. .
.
Ključne reči:
.
Sažetak
.
Reference
References:
[1]van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10. PMID: 21565397.
[2]Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int. 2020 Aug;44(8):1564-1576. doi: 10.1002/cbin.11359. Epub 2020 Apr 18. PMID: 32281704.
[3]Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287.
[4]Zugazagoitia J, Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5. PMID: 34985925.
[5]Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA,et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. PMID: 34902832.
[6]Bernhardt EB, Jalal SI. Small Cell Lung Cancer. Cancer Treat Res. 2016;170:301-22. doi: 10.1007/978-3-319-40389-2_14. PMID: 27535400.
[7]Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Erratum in: Nat Rev Cancer. 2017 Nov 10;: PMID: 29077690.
[8]Kiseli M, Caglar GS, Yarci Gursoy A, Tasci T, Candar T, Akincioglu E,et al. Pro-Gastrin Releasing Peptide: A New Serum Marker for Endometrioid Adenocarcinoma. Gynecol Obstet Invest. 2018;83(6):540-545. doi: 10.1159/000488854. Epub 2018 Jun 13. PMID: 29898448.
[9]Fang L, Huang Z, Lin Y, Fu J, Liang X, Liu F. Clinical Application of Pro-Gastrin-Releasing Peptide. Clin Lab. 2018 Jul 1;64(7):1259-1268. doi: 10.7754/Clin.Lab.2018.180316. PMID: 30146822.
[10]Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N. Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25. PMID: 30145817.
[11]Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125-43. doi: 10.1007/978-94-017-7215-0_9. PMID: 26530364.
[12]Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metab Brain Dis. 2016 Jun;31(3):487-95. doi: 10.1007/s11011-016-9801-6. Epub 2016 Feb 5. PMID: 26847611.
[13]Xu CM, Luo YL, Li S, Li ZX, Jiang L, Zhang GX, Owusu L, Chen HL. Multifunctional neuron-specific enolase: its role in lung diseases. Biosci Rep. 2019 Nov 29;39(11):BSR20192
[14]Chen KN. [Small Cell Lung Cancer and TNM Staging]. Zhongguo Fei Ai Za Zhi. 2016 Jun 20;19(6):409-12. Chinese. doi: 10.3779/j.issn.1009-3419.2016.06.22. PMID: 27335307.
[15]Avasarala SK, Rickman OB. Endobronchial Therapies for Diagnosis, Staging, and Treatment of Lung Cancer. Surg Clin North Am. 2022 Jun;102(3):393-412. doi: 10.1016/j.suc.2022.01.004. Epub 2022 Apr 21. PMID: 35671763.
[16]Conforti F, Pala L, Vivanet G, Corti C, Catania C, Maiettini D, Varano G, Di Venosa B, Curigliano G, Salvini P, Berardi R, Ballatore Z, De Pas TM. High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. Lung Cancer. 2023 Feb;176:98-102. doi: 10.1016/j.lungcan.2023.01.004. Epub 2023 Jan 7. PMID: 36630822.
[17]Tran S, Bielle F. WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification. Curr Opin Oncol. 2022 Nov 1;34(6):670-675. doi: 10.1097/CCO.0000000000000903. Epub 2022 Sep 12. PMID: 36093875.
[18]Wang WZ, Shulman A, Amann JM, Carbone DP, Tsichlis PN. Small cell lung cancer: Subtypes and therapeutic implications. Semin Cancer Biol. 2022 Nov;86(Pt 2):543-554. doi: 10.1016/j.semcancer.2022.04.001. Epub 2022 Apr 6. PMID: 35398266.
[19]Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer. 1996 May;73(10):1227-32. doi: 10.1038/bjc.1996.235. PMID: 8630283.
[20]Ischia J, Patel O, Sethi K, Nordlund MS, Bolton D, Shulkes A, Baldwin GS. Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy. BJU Int. 2015 May;115(5):829-38. doi: 10.1111/bju.12886. Epub 2015 Jan 26. PMID: 25130393.
[21]Echeverría-Palacio CM, Agut T, Arnaez J, Valls A, Reyne M, Garcia-Alix A. Neuron-Specific Enolase in Cerebrospinal Fluid Predicts Brain Injury After Sudden Unexpected Postnatal Collapse. Pediatr Neurol. 2019 Dec;101:71-77. doi: 10.1016/j.pediatrneurol.2019.02.020. Epub 2019 Mar 5. PMID: 31023601.
[22]Topuzova MP, Alekseeva TM, Panina EB, Vavilova TV, Kovzelev PD, Portik OA, Skoromets AA. Vozmozhnost' ispol'zovaniia neĭron-spetsificheskoĭ enolazy kak biomarkera v ostrom periode insul'ta [The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(8. Vyp. 2):53-62. Russian. doi: 10.17116/jnevro201911908253. PMID: 31825363.
[23]Sosnin DY, Gal'kovich KR, Khovaeva YB, Gil'manov AZ. Comparative Content of Neuron-Specific Enolase in Human Blood Serum and Seminal Plasma. Bull Exp Biol Med. 2022 Jul;173(3):298-301. doi: 10.1007/s10517-022-05537-9. Epub 2022 Jul 18. PMID: 35844024.
[24]Kamata K, Uchida M, Takeuchi Y, Takahashi E, Sato N, Miyake Y, Okubo M, Kodama T, Yamaguchi K. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant. 1996 Jul;11(7):1267-70. PMID: 8672021.
[25]Dong J, Tong S, Shi X, Wang C, Xiao X, Ji W,.et al. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations. Cancer Manag Res. 2021 Jan 5;12:13607-13616. doi: 10.2147/CMAR.S285121. PMID: 33447080.
[26]Wójcik E, Kulpa JK, Sas-Korczyńska B, Korzeniowski S, Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res. 2008 Sep-Oct;28(5B):3027-33. PMID: 19031951.
[27]Winther B, Moi P, Paus E, Reubsaet JL. Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS. J Sep Sci. 2007 Nov;30(16):2638-46. doi: 10.1002/jssc.200700221. PMID: 17874417.
[28]Rossetti C, Abdel Qader A, Halvorsen TG, Sellergren B, Reubsaet L. Antibody-free biomarker determination: exploring molecularly imprinted polymers for pro-gastrin releasing peptide. Anal Chem. 2014 Dec 16;86(24):12291-8. doi: 10.1021/ac503559c. Epub 2014 Nov 26. PMID: 25397409.
[29]Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269-95. doi: 10.1146/annurev.ne.10.030187.001413. PMID: 3551759.
[30]Endo T, Hasegawa T, Tezuka Y, Kanai Y, Otani S, Yamamoto S, Tetsuka K, Sato Y, Endo S, Sohara Y. [Atypical pulmonary carcinoid tumor with abnormal elevation of serum gastrin-releasing peptide precursor: report of a case]. Kyobu Geka. 2008 Oct;61(11):993-5. Japanese. PMID: 18939440.
[31]Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res. 1997 Jan;3(1):123-7. PMID: 9815547.
[1]van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10. PMID: 21565397.
[2]Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int. 2020 Aug;44(8):1564-1576. doi: 10.1002/cbin.11359. Epub 2020 Apr 18. PMID: 32281704.
[3]Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287.
[4]Zugazagoitia J, Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5. PMID: 34985925.
[5]Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA,et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. PMID: 34902832.
[6]Bernhardt EB, Jalal SI. Small Cell Lung Cancer. Cancer Treat Res. 2016;170:301-22. doi: 10.1007/978-3-319-40389-2_14. PMID: 27535400.
[7]Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Erratum in: Nat Rev Cancer. 2017 Nov 10;: PMID: 29077690.
[8]Kiseli M, Caglar GS, Yarci Gursoy A, Tasci T, Candar T, Akincioglu E,et al. Pro-Gastrin Releasing Peptide: A New Serum Marker for Endometrioid Adenocarcinoma. Gynecol Obstet Invest. 2018;83(6):540-545. doi: 10.1159/000488854. Epub 2018 Jun 13. PMID: 29898448.
[9]Fang L, Huang Z, Lin Y, Fu J, Liang X, Liu F. Clinical Application of Pro-Gastrin-Releasing Peptide. Clin Lab. 2018 Jul 1;64(7):1259-1268. doi: 10.7754/Clin.Lab.2018.180316. PMID: 30146822.
[10]Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N. Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25. PMID: 30145817.
[11]Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125-43. doi: 10.1007/978-94-017-7215-0_9. PMID: 26530364.
[12]Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metab Brain Dis. 2016 Jun;31(3):487-95. doi: 10.1007/s11011-016-9801-6. Epub 2016 Feb 5. PMID: 26847611.
[13]Xu CM, Luo YL, Li S, Li ZX, Jiang L, Zhang GX, Owusu L, Chen HL. Multifunctional neuron-specific enolase: its role in lung diseases. Biosci Rep. 2019 Nov 29;39(11):BSR20192
[14]Chen KN. [Small Cell Lung Cancer and TNM Staging]. Zhongguo Fei Ai Za Zhi. 2016 Jun 20;19(6):409-12. Chinese. doi: 10.3779/j.issn.1009-3419.2016.06.22. PMID: 27335307.
[15]Avasarala SK, Rickman OB. Endobronchial Therapies for Diagnosis, Staging, and Treatment of Lung Cancer. Surg Clin North Am. 2022 Jun;102(3):393-412. doi: 10.1016/j.suc.2022.01.004. Epub 2022 Apr 21. PMID: 35671763.
[16]Conforti F, Pala L, Vivanet G, Corti C, Catania C, Maiettini D, Varano G, Di Venosa B, Curigliano G, Salvini P, Berardi R, Ballatore Z, De Pas TM. High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. Lung Cancer. 2023 Feb;176:98-102. doi: 10.1016/j.lungcan.2023.01.004. Epub 2023 Jan 7. PMID: 36630822.
[17]Tran S, Bielle F. WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification. Curr Opin Oncol. 2022 Nov 1;34(6):670-675. doi: 10.1097/CCO.0000000000000903. Epub 2022 Sep 12. PMID: 36093875.
[18]Wang WZ, Shulman A, Amann JM, Carbone DP, Tsichlis PN. Small cell lung cancer: Subtypes and therapeutic implications. Semin Cancer Biol. 2022 Nov;86(Pt 2):543-554. doi: 10.1016/j.semcancer.2022.04.001. Epub 2022 Apr 6. PMID: 35398266.
[19]Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer. 1996 May;73(10):1227-32. doi: 10.1038/bjc.1996.235. PMID: 8630283.
[20]Ischia J, Patel O, Sethi K, Nordlund MS, Bolton D, Shulkes A, Baldwin GS. Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy. BJU Int. 2015 May;115(5):829-38. doi: 10.1111/bju.12886. Epub 2015 Jan 26. PMID: 25130393.
[21]Echeverría-Palacio CM, Agut T, Arnaez J, Valls A, Reyne M, Garcia-Alix A. Neuron-Specific Enolase in Cerebrospinal Fluid Predicts Brain Injury After Sudden Unexpected Postnatal Collapse. Pediatr Neurol. 2019 Dec;101:71-77. doi: 10.1016/j.pediatrneurol.2019.02.020. Epub 2019 Mar 5. PMID: 31023601.
[22]Topuzova MP, Alekseeva TM, Panina EB, Vavilova TV, Kovzelev PD, Portik OA, Skoromets AA. Vozmozhnost' ispol'zovaniia neĭron-spetsificheskoĭ enolazy kak biomarkera v ostrom periode insul'ta [The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(8. Vyp. 2):53-62. Russian. doi: 10.17116/jnevro201911908253. PMID: 31825363.
[23]Sosnin DY, Gal'kovich KR, Khovaeva YB, Gil'manov AZ. Comparative Content of Neuron-Specific Enolase in Human Blood Serum and Seminal Plasma. Bull Exp Biol Med. 2022 Jul;173(3):298-301. doi: 10.1007/s10517-022-05537-9. Epub 2022 Jul 18. PMID: 35844024.
[24]Kamata K, Uchida M, Takeuchi Y, Takahashi E, Sato N, Miyake Y, Okubo M, Kodama T, Yamaguchi K. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant. 1996 Jul;11(7):1267-70. PMID: 8672021.
[25]Dong J, Tong S, Shi X, Wang C, Xiao X, Ji W,.et al. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations. Cancer Manag Res. 2021 Jan 5;12:13607-13616. doi: 10.2147/CMAR.S285121. PMID: 33447080.
[26]Wójcik E, Kulpa JK, Sas-Korczyńska B, Korzeniowski S, Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res. 2008 Sep-Oct;28(5B):3027-33. PMID: 19031951.
[27]Winther B, Moi P, Paus E, Reubsaet JL. Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS. J Sep Sci. 2007 Nov;30(16):2638-46. doi: 10.1002/jssc.200700221. PMID: 17874417.
[28]Rossetti C, Abdel Qader A, Halvorsen TG, Sellergren B, Reubsaet L. Antibody-free biomarker determination: exploring molecularly imprinted polymers for pro-gastrin releasing peptide. Anal Chem. 2014 Dec 16;86(24):12291-8. doi: 10.1021/ac503559c. Epub 2014 Nov 26. PMID: 25397409.
[29]Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269-95. doi: 10.1146/annurev.ne.10.030187.001413. PMID: 3551759.
[30]Endo T, Hasegawa T, Tezuka Y, Kanai Y, Otani S, Yamamoto S, Tetsuka K, Sato Y, Endo S, Sohara Y. [Atypical pulmonary carcinoid tumor with abnormal elevation of serum gastrin-releasing peptide precursor: report of a case]. Kyobu Geka. 2008 Oct;61(11):993-5. Japanese. PMID: 18939440.
[31]Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res. 1997 Jan;3(1):123-7. PMID: 9815547.
Objavljeno
2025/06/13
Broj časopisa
Rubrika
Original paper
Sva prava zadržana (c) 2025 Ping Wang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.